The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...
Last year was a productive and exciting year for Alzheimer’s and dementia research. There were significant advancements in early detection, treatment, and risk management. Here are three significant d ...